Supplementary Fig. S3. All-grade adverse events (AEs) collected per protocol prior to June 2012 protocol amendment (median time on treatment 16 months [range, 0.3-29]) and grade ≥3 or other specified AEs (details below) collected subsequent to amendment. Data shows AEs by time to onset from first dose occurring in ≥15% of patients receiving ibrutinib. With the amendment, AE collection was limited to grade ≥3 AEs, serious AEs, AEs that led to dose reduction or treatment discontinuation, other malignancies of any grade, eye-related AEs grade ≥2, or major hemorrhage events were collected. Numbers of patients that were on study treatment at the beginning of each of the time intervals are noted as n below. Numbers at the end of each bar represent the percentage of patients with AE onset during that time interval.